extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16*
+
+CMS is explicitly testing whether combining GLP-1s with lifestyle supports can break the chronic-use inflation model. The BALANCE Model's requirement for evidence-based lifestyle interventions alongside medication addresses the adherence problem by potentially sustaining benefits after discontinuation, converting GLP-1s from chronic-use to intervention-plus-behavior-change model.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16*
+
+The BALANCE Model directly addresses low persistence by mandating lifestyle supports alongside GLP-1 coverage. CMS is testing whether behavioral interventions can sustain metabolic benefits after medication discontinuation, potentially solving the adherence problem that makes GLP-1s inflationary under current coverage models.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -35,6 +35,12 @@ GLP-1 persistence data illustrates why value-based care requires risk alignment:
 
 Medicare Advantage plans bearing full capitated risk increased GLP-1 prior authorization from <5% to nearly 100% within two years (2023-2025), demonstrating that even full-risk capitation does not automatically align incentives toward prevention when short-term cost pressures dominate. Both BCBS and UnitedHealthcare implemented universal PA despite theoretical alignment under capitation.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16*
+
+The BALANCE Model moves beyond touching value metrics to bearing full risk by adjusting capitated payment rates for obesity and increasing government reinsurance. This creates genuine downside exposure for participating plans, testing whether risk-bearing payment can make prevention profitable when combined with comprehensive intervention design.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-12-23-cms-balance-model-glp1-obesity-coverage.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md

@@ -7,9 +7,13 @@ date: 2025-12-23
 domain: health
 secondary_domains: [internet-finance]
 format: policy
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, cms, balance-model, medicare, medicaid, value-based-care, payment-model]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,12 @@ CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive
 PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 WHY ARCHIVED: First explicit federal test of the GLP-1 + VBC thesis — if it demonstrates net savings under risk-bearing, it validates the prevention-first attractor state; if it fails, it complicates it
 EXTRACTION HINT: Focus on the structural design (medication + lifestyle + payment adjustment) as a test of the attractor state thesis, not just as drug coverage policy
+
+
+## Key Facts
+- CMS BALANCE Model manufacturer RFA due January 8, 2026
+- Medicaid participation begins May 2026
+- Medicare Part D bridge demonstration begins July 2026
+- Full Medicare Part D participation begins January 2027
+- Model testing concludes December 2031
+- CMS negotiates drug pricing centrally on behalf of participating plans